ADAR1 Capital Management logo

ADAR1 Capital Management

Description

ADAR1 Capital Management is an investment firm.

Investor Profile

ADAR1 Capital Management has backed more than 10 startups, with 8 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.

Stage Focus

  • Post Ipo Equity (80%)
  • Series C (10%)
  • Series A (10%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Medical
  • Pharmaceutical
  • Genetics
  • Robotics
  • Health Diagnostics
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ADAR1 Capital Management frequently co-invest with?

BP
North America, California, United States, San Francisco
Co-Investments: 1
Nantahala Capital Management
North America, Connecticut, United States, New Canaan
Co-Investments: 3
Venrock Healthcare Capital Partners
North America, California, United States, Palo Alto
Co-Investments: 1
Co-Investments: 1
Frazier Life Sciences
North America, California, United States, Menlo Park
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 3
VC
North America, Georgia, United States, Alpharetta
Co-Investments: 1
SC
North America, Oregon, United States, Bend
Co-Investments: 2
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 4

What are some of recent deals done by ADAR1 Capital Management?

Aquestive Therapeutics

Warren, New Jersey, United States

Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems.

Pharmaceutical
Post Ipo EquityAug 14, 2025
Amount Raised: $85,000,000
Equillium

La Jolla, California, United States

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

BiopharmaBiotechnologyLife Science
Post Ipo EquityAug 11, 2025
Amount Raised: $30,000,000
BBOT

Palo Alto, California, United States

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

BiopharmaTherapeutics
Post Ipo EquityAug 11, 2025
Amount Raised: $261,000,000
atai Life Sciences

Munich, Bayern, Germany

Atai Life Sciences develops innovative mental health treatments that address significant unmet medical needs.

BiotechnologyLife ScienceMental HealthNeuroscienceTherapeutics
Post Ipo EquityJul 1, 2025
Amount Raised: $50,000,000
Quince Therapeutics

South San Francisco, California, United States

Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Post Ipo EquityJun 12, 2025
Amount Raised: $22,000,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityMay 27, 2025
Amount Raised: $80,000,000
Bambusa Therapeutics

Boston, Massachusetts, United States

Bambusa Therapeutics operates as biotechnology company.

BiotechnologyHealth CareLife ScienceMedical
Series AFeb 14, 2025
Amount Raised: $90,000,000
Monopar

Wilmette, Illinois, United States

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

BiopharmaBiotechnologyDeveloper ToolsHealth CareOncologyTherapeutics
Post Ipo EquityDec 20, 2024
Amount Raised: $40,000,000
Palvella Therapeutics

Wayne, Pennsylvania, United States

Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.

BiotechnologyHealth CareLife ScienceTherapeutics
Post Ipo EquityDec 13, 2024
Evommune

Palo Alto, California, United States

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

BiotechnologyHealth CareLife Science
Series COct 31, 2024
Amount Raised: $115,000,000